m6A-centered Drug Response Information

General Information of the Drug (ID: M6APDG02242)
Name
Rosiglitazone XR
Synonyms
Avandia; Nyracta; Venvia; Rosiglitazone Maleate [USAN]; Rosiglitazone maleate; BRL 49653C; Avandia (TN); Avandiaadministration for 6-12 weeks; BRL 49653-C; BRL-49653C; SB-206846; SB-210232; Rosiglitazone maleate (JAN/USAN); (+-)-5-(p-(2-(Methyl-2-pyridylamino)ethoxy)benzyl)-2,4-thiazolidinedione maleate (1:1); (+-)-5-[[4-2-(methyl]-2-pyridinylamino)ethoxy]phenyl]methyl]-2,4-thiazolidinedione,(Z)-2-butenedioate (1:1); 2,4-Thiazolidinedione, 5-((4-(2-(methyl-2-pyridinylamino)ethoxy)phenyl)methyl)-, (2Z)-2-butenedioate (1:1); 2,4-Thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino) ethoxy]phenyl]methyl]-, (2Z)-2-butenedioate (1:1); 2,4-Thiazolidinedione,5-((4-(2-(methyl-2-pyridinylamino)ethoxy)phenyl)methyl)-,(2Z)-2-butenedioate; 5-[[4-[2-[methyl(pyridin-2-yl)amino]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione; 5-{[4-({2-[methyl(pyridin-2-yl)amino]ethyl}oxy)phenyl]methyl}-1,3-thiazolidine-2,4-dione (2Z)-but-2-enedioate
    Click to Show/Hide
Status
Approved
Structure
3D MOL
2D MOL
Formula
C22H23N3O7S
InChI
1S/C18H19N3O3S.C4H4O4/c1-21(16-4-2-3-9-19-16)10-11-24-14-7-5-13(6-8-14)12-15-17(22)20-18(23)25-15;5-3(6)1-2-4(7)8/h2-9,15H,10-12H2,1H3,(H,20,22,23);1-2H,(H,5,6)(H,7,8)/b;2-1-
InChIKey
SUFUKZSWUHZXAV-BTJKTKAUSA-N
PubChem CID
5281055
TTD Drug ID
D0K5ER
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Peroxisome proliferator-activated receptor gamma (PPAR-gamma)
Fat mass and obesity-associated protein (FTO)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Peroxisome proliferator-activated receptor gamma (PPAR-gamma) is a therapeutic target for Rosiglitazone XR. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of Rosiglitazone XR through regulating the expression of Peroxisome proliferator-activated receptor gamma (PPAR-gamma). [1], [2]
References
Ref 1 The m(6)A demethylase FTO promotes the osteogenesis of mesenchymal stem cells by downregulating PPARG. Acta Pharmacol Sin. 2022 May;43(5):1311-1323. doi: 10.1038/s41401-021-00756-8. Epub 2021 Aug 30.
Ref 2 Expression of peroxisome proliferator-activated receptors (PPARs) in human urinary bladder carcinoma and growth inhibition by its agonists. Int J Cancer. 2003 May 1;104(5):597-602. doi: 10.1002/ijc.10980.